 The purpose of this study is to evaluate if immune-tolerance with Alum-formulated GAD Diamyd, in combination with high dose Vitamin D3, may delay or stop the autoimmune process leading to clinical type 1 diabetes in non-diabetic children with ongoing beta-cell autoimmunity as indicated by positive islet autoantibodies. 